36 related articles for article (PubMed ID: 8894583)
1. Effect of trovafloxacin on production of cytokines by human monocytes.
Khan AA; Slifer TR; Remington JS
Antimicrob Agents Chemother; 1998 Jul; 42(7):1713-7. PubMed ID: 9661009
[TBL] [Abstract][Full Text] [Related]
2. The Direction of the Antibacterial Effect of Rutin Hydrate and Amikacin.
Miklasińska-Majdanik M; Kępa M; Wąsik TJ; Zapletal-Pudełko K; Klim M; Wojtyczka RD
Antibiotics (Basel); 2023 Sep; 12(9):. PubMed ID: 37760765
[TBL] [Abstract][Full Text] [Related]
3. An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy.
Kumar A
Virulence; 2014 Jan; 5(1):80-97. PubMed ID: 24184742
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy for treatment of infections with gram-negative bacteria.
Tamma PD; Cosgrove SE; Maragakis LL
Clin Microbiol Rev; 2012 Jul; 25(3):450-70. PubMed ID: 22763634
[TBL] [Abstract][Full Text] [Related]
5. New antibiotics.
Friedland IR; Lutsar I
Curr Opin Pediatr; 1998 Feb; 10(1):41-5. PubMed ID: 9529636
[TBL] [Abstract][Full Text] [Related]
6. The chemistry and biological profile of trovafloxacin.
Brighty KE; Gootz TD
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():1-14. PubMed ID: 9222064
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of trovafloxacin in combination with ceftazidime, meropenem, and amikacin.
Milatovic D; Wallrauch C
Eur J Clin Microbiol Infect Dis; 1996 Aug; 15(8):688-93. PubMed ID: 8894583
[TBL] [Abstract][Full Text] [Related]
8. Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods.
Visalli MA; Bajaksouzian S; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1997 Jul; 41(7):1475-81. PubMed ID: 9210669
[TBL] [Abstract][Full Text] [Related]
9. Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill.
Burgess DS; Hastings RW
Diagn Microbiol Infect Dis; 2000 Sep; 38(1):37-41. PubMed ID: 11025182
[TBL] [Abstract][Full Text] [Related]
10. Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology.
Visalli MA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1998 Apr; 42(4):953-5. PubMed ID: 9559819
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa.
Tessier F; Quentin C
Eur J Clin Microbiol Infect Dis; 1997 Feb; 16(2):159-62. PubMed ID: 9105845
[TBL] [Abstract][Full Text] [Related]
12. In-vitro activity of trovafloxacin against sensitive and resistant aerobic bacteria using the standard microdilution broth method and Etest.
Dembry LM; Farrel PA; Orcutt DR; Gerrity LA; Andriole VT
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():35-42. PubMed ID: 9222068
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria.
Eliopoulos GM; Klimm K; Eliopoulos CT; Ferraro MJ; Moellering RC
Antimicrob Agents Chemother; 1993 Feb; 37(2):366-70. PubMed ID: 8452372
[TBL] [Abstract][Full Text] [Related]
14. In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone.
Gooding BB; Jones RN
Antimicrob Agents Chemother; 1993 Feb; 37(2):349-53. PubMed ID: 8043036
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of the new fluoroquinolone CP-99,219.
Neu HC; Chin NX
Antimicrob Agents Chemother; 1994 Nov; 38(11):2615-22. PubMed ID: 7872757
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
